Showing results (11-20 of 17) with videos related to
Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Bioorganic & Medicinal Chemistry Letters|August 18, 2020
Discovery of a phenylpyrazole amide ROCK inhibitor as a tool molecule for in vivo studiesZilun Hu, Cailan Wang, Peter W Glunz, et al.Bioorganic & Medicinal Chemistry Letters|November 10, 2009
Aroylguanidine-based factor Xa inhibitors: the discovery of BMS-344577Yan Shi, Chi Li, Stephen P O'Connor, et al.Bioorganic & Medicinal Chemistry Letters|November 2, 2011
Arylsulfonamidopiperidone derivatives as a novel class of factor Xa inhibitorsYan Shi, Stephen P O'Connor, Doree Sitkoff, et al.Bioorganic & Medicinal Chemistry Letters|October 11, 2005
Ketene aminal-based lactam derivatives as a novel class of orally active FXa inhibitorsYan Shi, Jing Zhang, Philip D Stein, et al.Journal of Medicinal Chemistry|June 15, 2022
Discovery of BMS-986339, a Pharmacologically Differentiated Farnesoid X Receptor Agonist for the Treatment of Nonalcoholic SteatohepatitisSusheel J Nara, Srinivas Jogi, Srinivas Cheruku, et al.Journal of Medicinal Chemistry|April 17, 2008
(3R,5S,E)-7-(4-(4-fluorophenyl)-6-isopropyl-2-(methyl(1-methyl-1h-1,2,4-triazol-5-yl)amino)pyrimidin-5-yl)-3,5-dihydroxyhept-6-enoic acid (BMS-644950): a rationally designed orally efficacious 3-hydroxy-3-methylglutaryl coenzyme-a reductase inhibitor with reduced myotoxicity potentialSaleem Ahmad, Cort S Madsen, Philip D Stein, et al.Journal of Medicinal Chemistry|April 1, 2026
Optimization of Covalent 6-Cyanoquinazoline KRASG12C Inhibitors for the Treatment of Solid TumorsJesse P Waldo, Paul J Krawczuk, Christopher B Kelly, et al.Pageof 2